Deferasirox dispersible tablets

Details for Australian Patent Application No. 2005230402 (hide)

Owner Novartis AG

Inventors Beauchamp, Catherine; Cassiere, Jean-Pierre; Battung, Florian

Agent Davies Collison Cave

Pub. Number AU-A-2005230402

PCT Pub. Number WO2005/097062

Priority 0408078.4 08.04.04 GB

Filing date 7 April 2005

Wipo publication date 20 October 2005

International Classifications

A61K 9/00 (2006.01) Medicinal preparations characterised by special physical form

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 31/41 (2006.01) - having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

Event Publications

28 September 2006 PCT application entered the National Phase

  PCT publication WO2005/097062 Priority application(s): WO2005/097062

28 May 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005230403-Oligopeptides for reducing elevated blood urea concentration

2005230401-Pimecrolimus foam composition containing hexylene glycol, optionally oleyl alcohol, dimethylisosorbide and/or medium chain triglycerides